Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周低点，触及0.22美元。这一显著下跌反映了公司正经历艰难时期，该股票一年内下跌了85.8%。根据 InvestingPro 数据显示，公司市值已萎缩至仅124万美元，而技术指标表明该股票处于超卖区域。投资者目睹了公司市值在过去一年中的急剧下降，因为该股票在市场压力和行业特定逆风中 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts ...

Dr. Young’s presentation, titled “Applying Principles of FDA’s Project Optimus to Oncology and Non-Oncology Rare Diseases,” will take place on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the ...

Processa Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings ...

David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his stake in the company with a recent purchase of common stock. According to a ...

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs ...

Financial Health for Processa Pharmaceuticals is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.

Processa Pharmaceuticals, Inc. HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company ...

HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...